




SCIENTIA MEETINGS

Vaccines Summit-2021

September 20-22, 2021 | Online Meeting



Sponsors



Scientia Meetings

Website: <https://scientiammeetings.com/conferences/vaccines/>

Ph: 1-815-595-8049; Email: venky@sciresgroup.net

DAY 1: SEPTEMBER 20, 2021 (MONDAY)

Keynote Presentations

EST (Eastern Time Zone)

08:55-09:00 Introduction: Opening Ceremony

Session Chair: **David Weiner**, Executive Vice President, Director, Vaccine & Immunotherapy Center, The Wistar Institute

09:00-09:30 Presentation Title: **The Evolution of Vaccinology**

Stanley Plotkin, Consultant and Emeritus Professor of the University of Pennsylvania, Vaxconsult, LLP

09:30-10:00 Presentation Title: **Exciting progress with malaria vaccines**

Adrian V. Hill, Director, The Jenner Institute, Nuffield Department of Medicine, University of Oxford

10:00-10:30 Presentation Title: **Synthetic DNA Approaches for Immunization and Immunotherapy**

David Weiner, Executive Vice President, Director, Vaccine & Immunotherapy Center, The Wistar Institute

10:30-11:00 Presentation Title: **Study of Adaptive Responses to SARS CoV2**

Alessandro Sette, Professor and Member, Infectious Disease and Vaccine Center, La Jolla Institute for Immunology

Break 11:00-11:10

Session Chair: **Gregory C. Gary**, Duke University

11:10-11:40 Presentation Title: **mRNA-1273: A Summary of Current Data and a View to the Future**

Jacqueline Miller, Senior Vice President, Therapeutic Area Head, Infectious Diseases, Moderna

11:40-12:10 Presentation Title: **Mitigating Future Pandemics: New Threats and Strategies to Consider**

Gregory C. Gray, Duke University

12:10-12:40 Presentation Title: **COVID-19: Developing a Vaccine During a Pandemic**

Dan Barouch, Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center

12:40-13:10 Presentation Title: **PfSPZ vaccines: From concept to proof of principle to genetically attenuated late arresting replication competent PfSPZ vaccine manufactured in bioreactors for use in malaria elimination campaigns**

Stephen L. Hoffman, Chief Executive and Scientific Officer, Sanaria Inc.

Break 13:10-13:30

Session Chair: **Farshad Guirakhoo**, Chief Scientific Officer, Vaxxinity

13:30-14:00 Presentation Title: **Vaccine, a cornerstone in immunotherapy for cancer; more than a T cell priming tool**

Samir N. Khleif, Director, Jeannie and Tony Loop Immuno-Oncology Research Laboratory, Lombardi Comprehensive Cancer Center

14:00-14:30 Presentation Title: **Development of Novel T cell Targeting Vaccines**

Daniel F. Hoft, Director, Division of Infectious Diseases, Allergy & Immunology, Department of Internal Medicine, Saint Louis University Medical Center

14:30-15:00 Presentation Title: **Immune correlates of protection and activation of immune cells after the challenge: From Ebola to COVID-19**

Alexander Bukreyev, Departments of Pathology and Microbiology & Immunology, Galveston National Laboratory, University of Texas Medical Branch

15:00-15:30 Presentation Title: **Development of Next Generation UB-612 Vaccine**

Farshad Guirakhoo, Chief Scientific Officer, Vaxxinity

15:30-16:00 Presentation Title: **Computational design of immune-focused SARS-CoV-2 nanoparticles**

Daniel Kulp, Associate Professor, Vaccine & Immunotherapy Center, The Wistar Institute

16:00-16:30 Presentation Title: **Development of a transmission blocking multivalent Covid-19 vaccine**

Nikolai Petrovsky, Director of Endocrinology, Flinders University

16:30-17:00 Presentation Title: **Pandemics unveil major shortcoming in contemporary vaccine design: Too little, too late**

Geert vanden Bossche, Coimeva Comm. Ven., Belgium

17:00-17:10 Questions & Panel Discussion

Poster Presentations

17:10-17:25 Presentation Title: **A novel tool to enable multivalent vaccine development for influenza and coronavirus**

Scott Fu, Filed Application Scientist

17:25-17:40 Presentation Title: **A Bi-Antigen Recombinant Subunit SARS-CoV-2 Vaccine comprising S1 Subunit and N protein, expressed in Pichia pastoris: A Low-cost, Safe and Effective Candidate Designed for Developing Countries**

Ganesh Kumraj, Techinvention Lifecare Pvt. Ltd

DAY 2: SEPTEMBER 21, 2021 (TUESDAY)

EST (Eastern Time Zone)

Session Chair: **Yongjun Sui**, The National Institutes of Health

- 08:00-08:20 Presentation Title: **Development of a versatile one-shot vaccine targeting platform**
Alonso Sylvie, National University of Singapore
- 08:20-08:40 Presentation Title: **Vaccine Hesitancy: The Next Challenge in the Fight Against COVID-19**
Niko Morozov, Sackler School of Medicine, Tel Aviv University
- 08:40-09:00 Presentation Title: **Ebola and SARS-CoV-2: CHO-based manufacturing provides high quality subunit-vaccine candidates and diagnostics**
Paco Pino, ExcellGene
- 09:00-09:20 Presentation Title: **Intranasal mucosal vaccine mediated protection against SARS-CoV-2 transmission in rhesus macaques**
Yongjun Sui, The National Institutes of Health

Break 09:20-09:30

- 09:30-09:50 Presentation Title: **Preclinical Immunogenicity Characterization of ARCT-021 SARS-CoV-2 Vaccine**
Sean Sullivan, Arcturus Therapeutics
- 09:50-10:10 Presentation Title: **Minimizing Covid-19 deaths by accelerated vaccination strategies despite limited vaccine supply**
Patrick Hunziker, University Hospital Basel
- 10:10-10:30 Presentation Title: **NIAID Preclinical Services Facilitate SARS-CoV-2 Vaccine Product Development by Standardizing the Microneutralization Assay for Phase III Vaccine Trials**
Janet Lathey, DMID/NIAID/NIH
- 10:30-10:50 Presentation Title: **Nasal nanoparticulate vaccine for toxoplasmosis**
Didier BETBEDER, VAXINANO

Break 10:50-11:00

Session Chair: **Philip Felgner**, University of California, Irvine

- 11:00-11:20 Presentation Title: **Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA Vaccination**
Philip Felgner, University of California, Irvine
- 11:20-11:40 Presentation Title: **ZyCoV-D COVID-19 DNA Vaccine**
Erin K Spiegel, PharmaJet, Inc.
- 11:40-12:00 Presentation Title: **Characterization of antibody epitopes in SARS-CoV-2 natural infection and vaccination, and prediction of effects of mutations on immune response with Serum Epitope Repertoire Analysis (SERA)**
John Shon, Serimmune
- 12:00-12:20 Presentation Title: **Generation of a gp96-Based SARS-CoV-2 Vaccine (ZVX-60) to Induce Long-Lived Memory T-cell Responses Against COVID-19**
Natasa Strbo, Heat Biologics

Break 12:20-12:30

- 12:30-12:50 Presentation Title: **Background Rates for Severe Cutaneous Reactions in the US: Contextual Support for Safety Assessment of Novel COVID-19 Vaccines**
Diane Gubernot, US Food and Drug Administration
- 12:50-13:10 Presentation Title: **Incorporating the Novel Complement Peptide-Derived Immunostimulant CPDI-02 with Nanoscale Dosage Forms for Mucosal Vaccines**
Joseph A. Vetro, University of Nebraska Medical Center
- 13:10-13:30 Presentation Title: **Cellular immune monitoring to support gene therapy trials including ELISPOT assays**
Magdalena Tary-Lehmann, Cellular Technology Limited
- 13:30-13:50 Presentation Title: **Neutralizing Antibodies Against Coronaviruses**
Pamela J. Bjorkman, California Institute of Technology
- 13:50-14:10 Presentation Title: **Development of rapidly deployable and broadly effective COVID-19 vaccines**
Louis D Falo Jr, University of Pittsburgh

Break 14:10-14:20

- 14:20-14:40 Presentation Title: **COVID-19 Vaccination and the Daily Cases, Hospitalizations and Death Rates: a Case Study of Tennessee in the United States**
Ali Roghani, University of Utah
- 14:40-15:00 Presentation Title: **Expression of CRM197 and Other Vaccine Carrier Proteins in an Engineered E. coli**
Andrew Lees, Fina Biosolutions
- 15:00-15:20 Presentation Title: **Clinical Translation of a Liposome-based RBD vaccine for COVID-19**
Wei-Chiao Huang, POP Biotechnologies
- 15:20-15:40 Presentation Title: **A synthetic peptide CTL vaccine confers protection from SARS-CoV-2 challenge in rhesus macaques**
Scott Burkholz, Flow Pharma
- 15:40-16:00 Presentation Title: **Novel next generation “universal” SARS CoV-2 vaccine (COVE-001)**
Thomas Tillett, MBF Therapeutics

Break 16:00-16:10

Session Chair: **Trudy Morrison**, University of Massachusetts Medical School

- 16:10-16:30 Presentation Title: **Substantial impact of post-vaccination contacts on cumulative infections during viral epidemics**
Nash D. Rochman, The National Institutes of Health
- 16:30-16:50 Presentation Title: **Mucosal vaccine approaches to elicit tissue resident memory (TRM) cells against respiratory pathogens**
Jay Kolls, Tulane School of Medicine
- 16:50-17:10 Presentation Title: **Maternal Immunization for Protection of Neonates from RSV**
Trudy Morrison, University of Massachusetts Medical School
- 17:10-17:30 Presentation Title: **Development of a vaccine to prevent or reduce Epstein-Barr virus diseases**
Jeffrey Cohen, National Institutes of Health

DAY 3: SEPTEMBER 22, 2021 (WEDNESDAY)

Keynote Presentations

EST (Eastern Time Zone)

Session Chair: **Pragya D Yadav**, ICMR-National Institute of Virology, Pune

- 08:00-08:30 Presentation Title: **RelCovaxTM, a second-generation multivalent SARS-CoV-2 vaccine candidate designed to meet global vaccination demands**
Robert W Malone, Vaccines and Biotechnology, RW Malone MD, LLC: Consultancy and Analytics in the Biosector
- 08:30-09:00 Presentation Title: **Platelet-myeloid cell aggregates play a key role in vaccine-induced trained innate immunity protecting macaques against SIV**
Jay A. Berzofsky, Chief, Vaccine Branch, Center for Cancer Research, NCI
- 09:00-09:30 Presentation Title: **Development of an inactivated SARS-CoV-2 vaccine candidate BBV152 and its response towards variant of concern**
Pragya D Yadav, ICMR-National Institute of Virology, Pune
- 09:30-10:00 Presentation Title: **Cancer Vaccines Are Back: this time to Stay**
Pirouz Daftarian, MBLI and CrowenbIO

Break 10:00-10:10

- 10:10-10:30 Presentation Title: **The Language of Vaccine Confidence: Lessons from the COVID-19 Vaccine Rollout**
Mark Miller, de Beaumont Foundation
- 10:30-10:50 Presentation Title: **A modeling path through epidemiology, virology, and immunology to SARS-CoV-2 vaccine composition decisions**
Jim Koopman, Developing Theory that Serves Public Health
- 10:50-11:10 Presentation Title: **Prevention of Covid-19 Transmission Beyond the Needle: DCOY101, a novel antiviral fusion peptide-based prophylactic nasal spray**
Barbara Hibner & Shahin Gharakhanian, DECOY Therapeutics
- 11:10-11:30 Presentation Title: **Customer Case Studies of Rapid Vaccine Analysis for Corona, Influenza, and more**
Scott Fu, Filed Application Scientist
- 11:30-11:50 Presentation Title: **Patient-specific dendritic cell vaccines for cancer and COVID-19**
Robert O. Dillman, AIVITA Biomedical Inc
- 11:50-12:10 Presentation Title: **Agnostic Cancer Vaccine: Synergistic Interaction of Oxaliplatin and Oncolytic Virus**
J. Milburn Jessup, Washington DC Veterans Affairs Medical Center

Break 12:10-12:20

12:20-12:40	Presentation Title: An Env-Gag VLP mRNA vaccine induces broad-spectrum neutralization and protects macaques from heterologous tier-2 SHIV infection Paolo Lusso , NIH
12:40-13:00	Presentation Title: Efficacy of an epithelial stem cell-based AIDS vaccine to induce immune responses and control transmission Marie-Claire Gauduin , Texas Biomedical Research Institute
13:00-13:20	Presentation Title: Innate cell markers that predict anti-HIV neutralizing antibody titers in vaccinated macaques Van Tilbeurgh , CEA
13:20-13:40	Presentation Title: Harnessing public B cell responses with pathway-amplifying vaccines Daniel Lingwood , The Ragon Institute of MGH, MIT and Harvard
13:40-14:00	Presentation Title: OVX836, NP-based universal influenza vaccine candidate: Results of Phase 2A Clinical Trial Alexandre Le Vert , Osivax
Break 14:00-14:10	
14:10-14:30	Presentation Title: ALFQ: A Potent Adjuvant for a peptide vaccine Carl R Alving , WRAIR, US Military HIV Research Program
14:30-14:50	Presentation Title: Vaccination with a lymph node targeted Amphiphile-CpG adjuvant promotes potent cellular and humoral immunity to SARS-CoV-2 protein subunit antigens Peter DeMuth , Elicio Therapeutics
14:50-15:10	Presentation Title: Building biomanufacturing capabilities in the kingdom of Saudi Arabia via government entities consortium Turki I. Almugaiteeb , Research Product Development Innovations Company (RPD)
15:10-15:30	Presentation Title: Short-term blockade of BCG induced IL-10 sustains long term protection against Mycobacterium tuberculosis infection in mice Varun Dwivedi , Texas Biomedical Research Institute
15:30-15:50	Presentation Title: MVX01: A global, serotype-independent, pneumococcal protein fusion vaccine candidate Kevin P Killeen , Matrivax
Break 15:50-16:00	
16:00-16:20	Presentation Title: A highly immunogenic UVC-inactivated Sabin-based polio vaccine Stephen J. Dollery , Biological Mimetics, Inc
16:20-16:40	Presentation Title: Inactivated bacterial vaccine candidates against <i>Acinetobacter baumannii</i> Gregory J. Tobin , Biological Mimetics, Inc
16:40-17:00	Presentation Title: Cold-Chain Elimination and Needle-free Administration of Vaccines Upon the Application of Thin Film Freezing Technology Robert O. Williams III , The University of Texas at Austin
17:00-17:20	Presentation Title: Per oral immunization with nanoparticle vaccines induces protective immunity against genital Chlamydia challenge Vjollca Konjufca , Southern Illinois University
17:20-17:40	Meetings, Pannel Discussions and Colaborations
Closing	

Vaccines Summit-2021

September 20-22, 2021 | Online Meeting

<https://scientiameetings.com/conferences/vaccines/>